Search in:

Advanced search

Expert Review of Clinical Pharmacology Volume 9, 2016 - Issue 1

Submit an article Journal homepage

410

Views

CrossRef citations to date

Altmetric

Drug Profiles

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity

Khawla F AliComprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medical College, New York, NY, USA

Alpana P ShuklaComprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medical College, New York, NY, USA

Louis J AronneComprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]

Pages 27-34 | Published online: 29 Oct 2015

Cite this article
https://doi.org/10.1586/17512433.2016.1100072
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of particular note have been highlighted as:
Google Scholar

**Of interest

World Health Organization. Obesity and overweight [Internet]. WHO Media Centre [ updated 2015; cited 2015 Jun 1]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
Google Scholar
Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012;(82):1–8.
Google Scholar
Finkelstein EA, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–31.
PubMed Web of Science ®Google Scholar
Reece AS. Hypothalamic opioid-melanocortin appetitive balance and addictive craving. Med Hypotheses. 2011;76(1):132–137.
PubMed Web of Science ®Google Scholar
Krude H, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–157.
PubMed Web of Science ®Google Scholar
Greenway FL, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–39.
PubMed Web of Science ®Google Scholar

**The first Phase II clinical trial assessing efficacy and safety of NB compared to placebo

Caixas A, et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419–1427.
PubMed Web of Science ®Google Scholar
Pennock RL, Hentges ST. Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons. J Neurosci. 2011;31(1):281–288.
PubMed Web of Science ®Google Scholar
Cowley MA, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480–484.
PubMed Web of Science ®Google Scholar
Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res. 2004;59:395–408.
PubMedGoogle Scholar
Huszar D, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131–141.
PubMed Web of Science ®Google Scholar
Ollmann MM, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997;278(5335):135–138.
PubMed Web of Science ®Google Scholar
Yaswen L, et al. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5(9):1066–1070.
PubMed Web of Science ®Google Scholar
Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8(1):21–34.
PubMed Web of Science ®Google Scholar
Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–626.
PubMed Web of Science ®Google Scholar
Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142–152.
PubMed Web of Science ®Google Scholar
Nau JY. Mysimba, an American appetite suppressant and the logic of the single European market. Rev Med Suisse. 2015;11(470):890–891.
PubMedGoogle Scholar
Ascher JA, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395–401.
PubMed Web of Science ®Google Scholar
Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology. 2007;32(4):822–834.
PubMed Web of Science ®Google Scholar
Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a “thrifty” genotype underlying the metabolic syndrome? Eur J Pharmacol. 2003;480(1–3):125–131.
PubMed Web of Science ®Google Scholar
Thomas SA, Palmiter RD. Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav Neurosci. 1997;111(3):579–589.
PubMed Web of Science ®Google Scholar
Yang ZJ, et al. Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size. Pharmacol Biochem Behav. 1997;58(3):631–635.
PubMed Web of Science ®Google Scholar
Wellman PJ. Modulation of eating by central catecholamine systems. Curr Drug Targets. 2005;6(2):191–199.
PubMed Web of Science ®Google Scholar
Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014;13(6):831–841.
PubMed Web of Science ®Google Scholar
Settle EC, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21(3):454–463.
PubMed Web of Science ®Google Scholar
Jain AK, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10(10):1049–1056.
PubMedGoogle Scholar
Anderson JW, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633–641.
PubMedGoogle Scholar
Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101(4):491–503.
PubMed Web of Science ®Google Scholar
Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359(7):715–721.
PubMed Web of Science ®Google Scholar
Gosnell BA, Levine AS. Reward systems and food intake: role of opioids. Int J Obes (Lond). 2009;33(Suppl 2):S54–8.
Google Scholar
Obese FY, et al. Long-term feed intake regulation in sheep is mediated by opioid receptors. J Anim Sci. 2007;85(1):111–117.
PubMed Web of Science ®Google Scholar
Brown DR, Holtzman SG. Suppression of deprivation-induced food and water intake in rats and mice by naloxone. Pharmacol Biochem Behav. 1979;11(5):567–573.
PubMed Web of Science ®Google Scholar
Holtzman SG. Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharmacol Exp Ther. 1974;189(1):51–60.
PubMed Web of Science ®Google Scholar
Kurbanov DB, et al. Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats. J Psychopharmacol. 2012;26(9):1244–1251.
PubMed Web of Science ®Google Scholar
Spiegel TA, et al. Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav. 1987;40(2):135–141.
PubMed Web of Science ®Google Scholar
Atkinson RL, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985;38(4):419–422.
PubMed Web of Science ®Google Scholar
Maggio CA, et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res Bull. 1985;14(6):657–661.
PubMed Web of Science ®Google Scholar
Malcolm R, et al. A controlled trial of naltrexone in obese humans. Int J Obes. 1985;9(5):347–353.
PubMed Web of Science ®Google Scholar
Greenway FL, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898–4906.
PubMed Web of Science ®Google Scholar

**A larger Phase II clinical trial assessing efficacy and safety of NB compared to placebo

Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
PubMed Web of Science ®Google Scholar

**The COR-I trial: first Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

Apovian CM, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943.
PubMed Web of Science ®Google Scholar

**The COR-II trial: Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

Wadden TA, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.
PubMed Web of Science ®Google Scholar

**The COR-BMOD trial: Phase III clinical trial assessing clinical efficacy of NB in association with behavior modification.

Hollander P, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
PubMed Web of Science ®Google Scholar

**The COR-D trial: Phase III clinical trial assessing clinical efficacy of NB in diabetes mellitus patients.

Contrave [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2014.
Google Scholar
Apovian CM, Louis Arrone, Powell AG. Clinical management of obesity. 1st ed. West Islip (NY): Professional Communications, Inc; 2015.
Google Scholar
Cardiovascular outcomes study of Naltrexone SR/Bupropion SR in overweight and obese subjects with cardiovascular risk factors (The Light Study) [Internet]. [cited 2015 Jul 1]. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01601704.
Google Scholar
News, C.C. Clinical trial testing safety of obesity drug contrave halted; 50 percent interim data released by the study’s executive committee [Internet]. [cited 2015 Aug 25]. Cleveland (OH): Cleveland Clinic Newsroom; 2015 [ updated 2015]. Available from: http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/2015-5-12-clinical-trial-testing-safety-of-obesity-drug-contrave-halted.
Google Scholar
Orexigen Therapeutics, I. Orexigen therapeutics provides statement on termination of the light study and updates on contrave collaboration with takeda pharmaceuticals [Internet]. [cited 2015 Jul 1]. San Diego (CA): Orexigen Therapeutics, Inc.; 2015 [ updated 2015]; Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=2047312.
Google Scholar
Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S–225S.
PubMed Web of Science ®Google Scholar
Sjostrom L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–752.
PubMed Web of Science ®Google Scholar
Sjostrom L, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.
PubMed Web of Science ®Google Scholar
Kashyap SR, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36(8):2175–2182.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity

References

**Of interest

**The first Phase II clinical trial assessing efficacy and safety of NB compared to placebo

**A larger Phase II clinical trial assessing efficacy and safety of NB compared to placebo

**The COR-I trial: first Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

**The COR-II trial: Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

**The COR-BMOD trial: Phase III clinical trial assessing clinical efficacy of NB in association with behavior modification.

**The COR-D trial: Phase III clinical trial assessing clinical efficacy of NB in diabetes mellitus patients.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity

References

**Of interest

**The first Phase II clinical trial assessing efficacy and safety of NB compared to placebo

**A larger Phase II clinical trial assessing efficacy and safety of NB compared to placebo

**The COR-I trial: first Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

**The COR-II trial: Phase III clinical trial assessing clinical efficacy of NB compared to placebo.

**The COR-BMOD trial: Phase III clinical trial assessing clinical efficacy of NB in association with behavior modification.

**The COR-D trial: Phase III clinical trial assessing clinical efficacy of NB in diabetes mellitus patients.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date